OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Biran on the DREAMM-7 Trial in Multiple Myeloma

July 11th 2024

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Dr Mehra on the Implications of the E3311 Trial in HPV+ Oropharynx Cancer

July 11th 2024

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Dr Pal on the Preliminary Efficacy of DFF332 in Advanced ccRCC

July 11th 2024

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Dr Garfall on Long-Term Data for Teclistamab in Relapsed/Refractory Myeloma

July 11th 2024

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Dr Braun on Selecting Immune Checkpoint Inhibitor–Based Combos in ccRCC

July 11th 2024

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma

Dr Hunter on the Management Ruxolitinib-Associated AEs in Myelofibrosis

July 11th 2024

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Dr Krishnan on Patient Characteristics Associated With Early Relapse in Multiple Myeloma

July 11th 2024

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Dr Trent on The Current Standard of Care and Existing Unmet Needs for Patients with GIST

July 11th 2024

Jonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.

Dr Danilov on the Evolution of MCL Treatment

July 11th 2024

Alexey Danilov, MD, PhD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Dr Phillips on Evolving Treatment Strategies in Both MCL and CLL

July 11th 2024

Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.

Dr Wirth on Questions About Selpercatinib Use in Advanced RET Fusion+ Thyroid Cancer

July 11th 2024

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Dr Fürstenau on the Efficacy of Frontline Venetoclax-Based Combinations in CLL

July 10th 2024

Moritz Fürstenau MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Dr Gerds on Disease Progression Patterns in Low-Risk Myelofibrosis

July 10th 2024

Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis.

Dr Sundaresan on Reasons Why Patients With Pancreatic Cancer May Decline Treatment

July 10th 2024

Tilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.

Dr Davis on the Investigation of Neratinib Plus Trastuzumab Deruxtecan in Advanced HER2+ Solid Tumors

July 10th 2024

Andrew Davis, MD, discusses an ongoing phase 1 trial combining neratinib and trastuzumab deruxtecan in metastatic HER2-positive solid tumors.

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCC

July 10th 2024

Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.

Dr Philip on the Development of T-Cell Dysfunction in Liver Cancer and Melanoma Cell Models

July 9th 2024

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

Dr Leidner on the Investigation of TCR-Engineered T-Cell Immunotherapy in Solid Tumors

July 9th 2024

Rom S. Leidner, MD, discusses the investigation of T-cell receptor–engineered T-cell immunotherapy for select patients with solid tumors.

Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors

July 9th 2024

Sarwish Rafiq, PhD, discusses how engineering metabolically fit, memory rich CAR T-cells may address barriers to CAR T-cell efficacy in solid tumors.

Dr Biran on Future Research Directions in Multiple Myeloma

July 8th 2024

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.